To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n ¼ 43). Genomic fusions were amplified by single step PCR in all cases whereas only 22 (51%) were single step RT-PCR positive. Importantly, FIP1L1-PDGFRA was detected in two cases that initially tested negative by RT-PCR or fluorescence in situ hybridization. Absolute quantitation of the fusion by real-time PCR from genomic DNA (gDNA) using patient-specific primer/probe combinations at presentation (n ¼ 13) revealed a 40-fold variation between patients (range, 0.027-1.1 FIP1L1-PDGFRA copies/haploid genome). In follow up samples, quantitative analysis of gDNA gave 1-2 log greater sensitivity than RQ-PCR of cDNA. Minimal residual disease assessment using gDNA showed that 11 of 13 patients achieved complete molecular response to imatinib within a median of 9 months (range, 3-17) of starting treatment, with a sensitivity of detection of up to 1 in 10 5 . One case relapsed with an acquired D842V mutation. We conclude that detection of FIP1L1-PDGFRA from gDNA is a useful adjunct to standard diagnostic procedures and enables more sensitive follow up of positive cases after treatment.
Introduction
Persistent eosinophilia can arise from clonal disorders of the bone marrow, or from a number of reactive conditions. The diagnosis of idiopathic hypereosinophilic syndrome is one of exclusion and the disease is characterized as a persistent state of unexplained eosinophilia (total eosinophil count 41.5 Â 10 9 /l) for longer than 6 months, with evidence of organ dysfunction due to eosinophilic tissue infiltration and the consequent release of their granules and toxic contents. 1 If clonal proliferation of eosinophils can be shown, then the disease should be reclassified as chronic eosinophilic leukaemia and treated accordingly. 2, 3 The finding of a cryptic interstitial deletion on chromosome 4q12 that fuses the FIP1-Like-1 gene (FIP1L1) to the plateletderived growth factor receptor a gene (PDGFRA) revolutionized the diagnosis of chronic eosinophilic leukaemia. 4, 5 Importantly, the presence of the FIP1L1-PDGFRA fusion gene predicts a favourable response to the small molecule inhibitor imatinib and most positive patients show dramatic responses to therapy with rapid normalization of peripheral eosinophil counts and achievement of nested or real-time quantitative reverse transcription polymerase chain reaction (RQ-PCR) negativity. [6] [7] [8] [9] [10] Identification of patients who are positive for FIP1L1-PDGFRA is therefore critical to appropriate clinical management.
11,12
Exclusion of FIP1L1-PDGFRA is also important as some patients may benefit from alternative therapies such as mepolizumab. 13 Unambiguous detection of FIP1L1-PDGFRA, however, is complicated by several factors. Fluorescence in situ hybridization (FISH) to detect heterozygous deletion of CHIC2, a surrogate marker for FIP1L1-PDGFRA, can be difficult because of the inherent background fluorescence of eosinophils 9 and the variability in the proportion of cells involved in the malignant clone, 14, 15 which is often low and may overlap with the intrinsic background false-positive rate of this technique. Reverse transcriptase polymerase chain reaction (RT-PCR) is complicated by the considerable diversity of break points within FIP1L1, the complex alternative splicing of FIP1L1 and the variable use of cryptic splice sites in the fusion gene. 4, 9, 16 Indeed, FIP1L1-PDGFRA transcripts can often only be detected by sensitive nested RT-PCR assays, even in previously untreated patients. 4, 11, 17 Nested RT-PCR has a greatly enhanced risk of contamination resulting in false-positive results, potentially leading to misdiagnosis and inappropriate treatment. Although real time quantitative RT-PCR (RQ-PCR) can detect FIP1L1-PDGFRA in many cases, 7 the diversity of mRNA fusions makes the design of workable primer/probe sets that are capable of detecting all variants very difficult. Currently it is unclear to what extent these concerns actually impact on current diagnostic methods to assess this, we have developed a multiplex Long-Range PCR (LR-PCR) technique to detect genomic DNA (gDNA) break points which are unique to each patient, enabling a definitive diagnosis. We demonstrate that the amplification of DNA break points enables more robust detection of FIP1L1-PDGFRA in patients at diagnosis and a more sensitive means of detecting minimal residual disease (MRD) in patients undergoing targeted therapy.
Materials and methods

Patient samples
Peripheral blood or bone marrow samples were referred for molecular diagnostic analysis following informed consent according to the Declaration of Helsinki. The use of residual material for research was approved by the South Wiltshire Research Ethics Committee. Of the cases analysed by RQ-PCR from cDNA, results are included from three (cases E359, E370 and E630) that were published in a previous study. 7 
Nested reverse transcriptase-PCR
Leukocytes were lysed with guanidium thiocyanate and total RNA extracted using Qiagen RNeasy system (Qiagen, West Sussex) following the manufacturers guidelines. The RNA was reverse transcribed into cDNA with random hexamers and tested for the adequate cDNA quality by amplification of the normal BCR gene as described earlier. 18 This test also excluded the presence of BCR-ABL. FIP1L1-PDGFRA was tested for by both single step and nested RT-PCR using primers FIP1E6-F1 (5 0 -CACCTGGAAGCATTAATGGAG-3 0 ) and PDA-R1 (5 0 -TGAG AGCTTGTTTTTCACTGGA-3 0 ) for first step and FIP1E6-F2 (5 0 -A GTTCCACTCTTAGAGGTAG-3 0 ) and PDA-R2 (5 0 -GGGACCGG CTTAATCCATAG-3 0 ) for the nested step, a procedure modified slightly from that described earlier. 4 For cases that were relapsed, the region of the fusion encoding the kinase domain was specifically amplified from cDNA using primers FIP.Ex. 10.1F (5 0 -CAGCAGGGAAGAACTGGAAACTCA-3 0 ) and PDA. Ex.22.1R (5 0 -GTGGTCTGGATGAGCAGAGACTGAG-3 0 ) in the first step followed by PDA.Ex16.1F (5 0 -TGTCCCCATGCTAGA AAGGAAAGAG-3 0 ) and PDA.Ex.22.2R (5 0 -CCTGAAGAGTGA CCATCCTGCTGT-3 0 ) in the second step. PCR products were directly sequenced using the second step primers.
Expand long-range PCR
Genomic DNA was extracted from peripheral blood leukocytes by standard procedures. For detection of genomic DNA break points, the Expand Long Template PCR System (Roche, Burgess Hill, UK) was used with System 2 and an annealing temperature of 64 1C according to the manufacturer's instructions. All primers were designed using Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) to be 23 bases long with a melting temperature of 66 1C. Fifteen FIP1L1 forward primers were designed approximately every 5 kb from FIP1L1 intron 5 to intron 16, with the exception of a region of approximately 12 kb in intron 10 for which primers could not be designed due to the highly repetitive nature of the sequence. For the purposes of the multiplex technique, the 15 FIP1L1 forward primers were split up into three mixes of five primers ensuring that the primers in each group were more than 15 kb apart to avoid amplification of more than one break point product (see Figure 1 and Figure 1 Positions of FIP1L1-screening primers and patient gDNA break points. The thick horizontal line represents the FIP1L1 gene from exon 9 to the end of exon 18 and the black vertical lines represent each exon. The FIP1L1 forward screening primers are represented by the horizontal arrows with their names and which of the screening mixes they are in, above, except the FIP1L1 int 5 (11403) forward primer which was included in Mix 1. The position of the respective genomic break point for each patient is represented by a vertical arrow, with the two smaller arrows showing break point locations of the two patients who were nested RT-PCR negative but gDNA multiplex positive. Table 1 Primers used in the multiplex gDNA PCR 
Mix
RQ-PCR of gDNA break points
Quantitative gDNA analysis was performed for 13 cases that were treated with imatinib and for whom presentation and at least three follow up samples were available. PDGFRA primers and probes were designed on Molecular Beacon software by Sigma (Gillingham, UK). For the PDGFRA probe to be suitable for detection of all possible break points it had to be designed in a very small region 3 0 of the exon 12 break point cluster region and therefore locked nucleic acids (LNA) were incorporated to increase specificity of the probe 19 LNA probe 5 0 -cctCccAa gActCcct-3 0 (capital letters indicate LNA oligos). All FIP1L1 patient-specific forward primers were designed using Primer3 with the same annealing temperature as the generic PDGFRA reverse primer (55 1C). The gDNA RQ-PCR was tested initially on FIP1L1-PDGFRA positive presentation samples, normal controls and no template controls to ensure patient-specific amplification of break points. The probe was also tested on serial dilutions of normal control DNA with the PDGFRA forward and reverse primers (PDGFRA-F: 5 0 -ACTAGTGCTTGG-TAAGTTCC-3; PDGFRA-R: 5 0 -CCTATAAATTGTAAAGTTGTGT GC-3 0 ) and on three patients with the appropriate FIP1L1 forward primers to ensure the assays conformed to the EAC criteria, 20 that is, a DRn of at least one in diagnostic material and an efficiency 495%. Absolute quantification was used for determining the levels of gDNA fusion at presentation and relative quantification was used to determine patients response to imatinib therapy.
Absolute quantification of gDNA fusions in pre-imatinib samples
Each patient-specific gDNA fusion was amplified using Hotstart PCR amplification conditions (AmpliTaq Gold, Roche) with 64 1C annealing temperature and 30 cycles. Each fusion was cloned using the TOPO pCR4 kit (Invitrogen, Paisley, UK), extracted, linearized by restriction digest, cleaned and quantified on a NanoDrop ND-1000 spectrophotometer. For each patient/primer/probe combination we estimated the routine analytical sensitivity of the gDNA assay to be o10 copies in a background of 10 4 -10 5 normal cells using 500 ng input gDNA using serial dilutions of plasmid DNA in normal control DNA (data not shown). The number of copies of the fusion for each patient sample was then calculated and serial dilutions of each patient-specific plasmid made into normal control gDNA (Roche). Each pre-imatinib sample was then compared against its plasmid standard curve. As a control for the amount of amplifiable gDNA for each sample we estimated the number of haploid genomes by RQ-PCR for the albumin gene. To do this, all patient samples were compared against a standard curve for the albumin gene using previously described conditions 21 and serial dilutions of human genomic DNA (Roche). Each result was then converted into estimates of the actual amounts of amplifiable gDNA in mg and multiplied by 3.3 Â 10 5 to estimate the number of amplifiable haploid genomes. 22, 23 PCRs were performed using PrimerDesign (Southampton, UK) master mix under standard conditions, with 5 ml of gDNA (approximately 100 ng). PCRs were set up on a RotorGene CAS1200 robot and run on the RotorGene 6000 platform (Cambridge, UK).
Relative quantification of gDNA fusions for MRD detection
The PDGFRA and albumin (ALB) gDNA probes and primers were tested on serial dilutions of normal control gDNA, to ensure that they gave good standard curves, as defined elsewhere. 20 Patient samples were then run with the appropriate forward primers and relative amounts of FIP1L1-PDGFRA calculated using the DC t method 24 with normalization against the ALB results for each sample. To assess the analytical sensitivity with which residual disease could be excluded for negative results, we estimated the number of haploid genomes as described above. The results for relative quantification were expressed as the ratio of gDNA FIP1L1-PDGFRA/ALB. All samples, negative controls and no template controls were run in triplicate and samples only classed as positive if amplification was seen at least in two of the three wells with a C t value of 40 or less.
FISH
FISH was performed on six patients for whom cytogenetic cultures were available, using the Poseidon FIP1L1-CHIC2-PDGFRA dual-labelled deletion break probe (Kreatech, Amsterdam, Holland) and hybridized as described earlier. 25 For all patients 100 interphase cells were scored.
RQ-PCR from cDNA
RQ-PCR from cDNA was performed as described 7 except the RotorGene CAS1200 robot and RotorGene 6000 were used, the probe was labelled with FAM and BHQ1 and 2 ml of cDNA was used for each reaction using PrimerDesign master mix. New forward primers were designed for two break points. As a control for cDNA quality and quantity, normal ABL transcripts were quantified by RQ-PCR as described earlier 20 and results were expressed as the ratio of FIP1L1-PDGFRA/ABL.
Results
Amplification of FIP1L1-PDGFRA from gDNA
We screened gDNA from 202 cases referred for IHES or persistent unexplained eosinophilia, none of whom had been treated with imatinib. We found that all cases previously determined to be positive by RT-PCR were also positive by gDNA multiplex LR-PCR (n ¼ 43; Figures 1 and 2) . Encouragingly, genomic fusions were amplified by single step PCR in all cases whereas only 22 (51%) of these samples were single step RT-PCR positive. Amplicons ranged in size from 404 bp-8.6 kb and in all cases were confirmed by sequence analysis, showing that the FIP1L1-PDGFRA junctions were unique to each patient.
Improved detection of FIP1L1-PDGFRA from gDNA compared with nested RT-PCR
Unexpectedly, FIP1L1-PDGFRA was detected by single step PCR of gDNA in two cases that had been previously scored as nested RT-PCR negative. Repeat samples from these patients were tested by RT-PCR and both were found to be positive (one case was positive in only two of three replicate nested reactions). Sequencing of the amplicons revealed typical mRNA fusions between FIP1L1 exon 13 for both patients and part of PDGFRA exon 12. Despite the fact that both initial cDNAs had passed our routine quality control procedure (qualitative amplification of normal BCR mRNA 18 ), we speculated that the discrepant results were due to relatively poor quality cDNA, possibly exacerbated by the known variability in FIP1L1-PDGFRA expression between cases. Quantitation of normal ABL transcripts by RQ-PCR revealed 1-2 Â 10 3 transcripts per 2 ml of cDNA, which is perfectly adequate to detect other fusions such as BCR-ABL in pretreatment specimens, but which is relatively low compared with the level of X10 4 (sensitivity X0.01%) that is generally considered as suitable quality for MRD analysis. 26 
Variability of FIP1L1-PDGFRA expression
Previous RQ-PCR studies revealed considerable variation in FIP1L1-PDGFRA expression levels in patients prior to imatinib treatment. 7 To investigate this further, we estimated the proportion of fusion-positive cells in pretreatment patient samples as assessed by RQ-PCR of gDNA fusion junctions compared with the ALB gene as a measure of total DNA. For each patient we designed specific gDNA primers that were used in combination with a generic probe. As expected, primer/probe combinations were specific to each patient (Figure 3a) and demonstrated linear results on analysis of a dilution series of presentation DNA (Figures 3b and c) . Absolute quantification of the fusion at presentation (n ¼ 13) by gDNA RQ-PCR revealed a median of 0.13 copies of FIP1L1-PDGFRA per haploid genome (equivalent to a median 13% fusion-positive cells) with a 40-fold variation between patients (range, 2.7-100% fusion-positive cells).
Comparison of gDNA RQ-PCR and FISH
The gDNA RQ-PCR results suggested that the clone size may be too small to be easily detected by FISH in some cases. Of the 13 cases analysed above, six had contemporaneous peripheral blood-derived fixed cells suitable for interphase FISH. As shown on Table 2 , the results between the two techniques were broadly concordant. The two patients with only 3% FIP1L1-PDGFRA cells estimated by gDNA RQ-PCR (cases E513 and E2002) had 6 and 4% deleted positive cells detectable by FISH compared with a background false-positive rate of 5%. 14, 15 This suggests that FISH screening alone might miss some FIP1L1-PDGFRA-positive cases. Improved detection and monitoring of FIP1L1-PDGFRA J Score et al
Comparison of cDNA and gDNA methods to assess the sensitivity of detecting MRD
Having established that amplification from gDNA was more reliable than cDNA for detection of FIP1L1-PDGFRA in preimatinib samples, we next went on to examine the utility of gDNA analysis for assessing levels of MRD. Initially, we designed patient-specific nested gDNA primers for seven cases and found that 11/31 post-imatinib data points were discordant when compared with nested RT-PCR, with 10/11 being gDNA positive, cDNA negative (not shown). This suggested that gDNA analysis was a more sensitive indicator of MRD. To examine this in more detail, we developed patient-specific RQ-PCR gDNA assays. We analysed 66 samples from 13 patients who underwent treatment with imatinib (median dose ¼ 100 mg/day, median follow-up ¼ 25 months; range, 9-58) and initially compared the results to those obtained by qualitative single step or nested RT-PCR.
Comparison of gDNA RQ-PCR and nested RT-PCR revealed large discrepancies with 49% (31/63) samples positive by gDNA RQ-PCR but only 31% (19/61) were positive by nested RT-PCR, again highlighting the inaccuracies of the standard RT-PCR technique. Nevertheless, MRD assessment using gDNA showed that 11 of 13 patients achieved a complete molecular response to imatinib within a median of 9 months (range, 3-17) of starting treatment (Figure 4 ). The median sensitivity with which FIP1L1-PDGFRA could be excluded was 1 in 30 000.
Two cases (E370 and E2245) failed to achieve a molecular response. Sequencing of the region encoding the FIP1L1-PDGFRa tyrosine kinase domain in the most recent samples revealed only normal sequence for E370, but E2245 had an A to T sequence change at position 2473, which is predicted to result in a D842V substitution. This sequence change was not detectable in the pre-imatinib sample ( Figure 5 ).
Comparison of gDNA and cDNA RQ-PCR
Of the 13 patients monitored using gDNA after imatinib treatment, nine were amenable to RQ-PCR analysis from cDNA because of limitations imposed by the position of the probe 7 and seven of these had sequential samples available for analysis. Of the 31 post-treatment data points available for comparison, five were discordant (gDNA positive, cDNA negative; see Figure 6 ). In contrast, there were no instances where cDNA-based RQ-PCR was positive and gDNA-based RQ-PCR was negative. The gDNA RQ-PCR also showed 1-2 logs higher sensitivity for exclusion of residual disease that tested negative for FIP1L1-PDGFRA compared with cDNA (Figures 4 and 6) .
Discussion
In contrast to other leukaemia-specific gene fusions, nested RT-PCR is routinely required to detect FIP1L1-PDGFRA in many pretreatment cases 4, 9 even when good quality cDNA is used. E243  E43  E359  E591  E759  E1025  E1279  E370  E630  E614  E1131 E606 E2245 Figure 4 Graph showing log reduction from patient-specific baselines in the levels of gDNA FIP1L1-PDGFRA fusion following time of start in imatinib therapy for 13 patients. The solid data points represent positive and empty data points represent negative results, respectively. Figure 5 Sequence electropheregrams showing the emergence of the imatinib resistance mutation in the PDGFRa kinase domain changing codon GAC (Asp) in the presentation sample to GTC (Val) in the relapse sample. Improved detection and monitoring of FIP1L1-PDGFRA J Score et al
Presentation Relapse
We tested several different FIP1L1 and PDGFRA primers but were unable to identify a combination that was able to routinely amplify fusions by single step amplification (not shown). To try and improve the detection of FIP1L1-PDGFRA, we developed a single step, multiplex long-range PCR technique based on detection of gDNA break points. We designed and optimized three multiplex PCRs each consisting of 5 forward primers spanning the break point region within FIP1L1 (intron 5 to intron 16) and a single reverse primer in PDGFRA intron 12. The multiplexes amplified FIP1L1-PDGFRA genomic junction sequences in all 43 cases previously shown to be fusion positive by single step or nested RT-PCR. FIP1L1-PDGFRA was also detected in two patients previously thought to be nested RT-PCR negative, despite the initial cDNAs having passed standard quality control criteria which have been proved to be robust for diagnostic detection of BCR-ABL. 18 On account of the high degree of variability in FIP1L1-PDGFRA expression between patients, we suggest that the minimum cDNA quality criteria similar to those employed for residual disease analysis 26 should also apply to diagnostic RT-PCRs for FIP1L1-PDGFRA. If these criteria are applied then it appears that nested RT-PCR is a robust technique to detect FIP1L1-PDGFRA in pretreatment cases.
We also found that the gDNA multiplex PCR easily detected FIP1L1-PDGFRA in two cases that were negative or borderline negative by FISH, however it is important to stress that our analysis was performed on peripheral blood rather than bone marrow. In our six cases, the median proportion of FISH-positive cells was only 20% compared with a median of 80% in 10 cases for whom bone marrow was analysed.
14 Although further comparative FISH data of blood and bone marrow are warranted, these results suggest that the absence of CHIC2 deleted cells by interphase FISH should be interpreted with caution when peripheral blood is used for analysis.
RQ-PCR from gDNA confirmed a considerable degree of variation in the proportion of FIP1L1-PDGFRA-positive cells between patients prior to imatinib therapy. However, this variation was much smaller (40-fold versus 1000-fold) than that previously described for FIP1L1-PDGFRA mRNA levels, 7 suggesting that the difficulties in RT-PCR detection is only partly because of variable clone size. This is consistent with the observation that gDNA PCR was able to amplify FIP1L1-PDGFRA junction sequences in all pre-imatinib cases by single step amplification, whereas only half were single step RT-PCR positive. For assessment of MRD following imatinib treatment, we demonstrated that gDNA RQ-PCR was 1-2 logs more sensitive than RNA-based analysis. Nevertheless, we found that 11 of 13 cases achieved a complete gDNA molecular response to imatinib in a median of 9 months, confirming the excellent response of this disease to targeted therapy. 4, 6, 8, 15 The superior Improved detection and monitoring of FIP1L1-PDGFRA J Score et al sensitivity of gDNA analysis may be particularly useful for novel approaches to disease management such as determination of optimal dosing for individual cases. 27 Analysis of gDNA also has an advantage in that results can be related readily to numbers of malignant cells, something that is problematic for RT-PCR-based approaches.
Of the two cases that did not achieve a complete molecular response, one was found to have a D842V mutation. This sequence variant has not been reported earlier in FIP1L1-PDGFRA, but is the most common mutation seen in imatinib-resistant, PDGFRA-mutated gastrointestinal stromal tumours.
28 D842V corresponds to the D816V mutation seen in systemic mastocytosis, an activating mutation that is also refractory to inhibition with imatinib. 29, 30 The suboptimal response in the second case was believed to be a consequence of poor treatment compliance.
In summary, the exquisite sensitivity of FIP1L1-PDGFRApositive cases to imatinib means that accurate detection of the fusion is very important for optimal clinical management. We have shown here that analysis of gDNA break points assists in the initial diagnosis of FIP1L1-PDGFRA-positive disease and consequently we have adopted this into our routine laboratory practice. We have also shown that analysis of gDNA break points provide a means to monitor MRD with high levels of sensitivity. Although this may be of benefit for specific research applications, this approach involves a considerable amount of work and it remains to be established if the extra log in sensitivity is of routine clinical benefit.
